Acquisition by Resnick Joshua of 16911 shares of Vor Biopharma at 4.26 subject to Rule 16b-3
| VOR Stock | USD 1.08 0.03 2.70% |
Slightly above 62% of Vor Biopharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Vor Biopharma suggests that many traders are alarmed. Vor Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Vor Biopharma. Many technical investors use Vor Biopharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Vor |
Filed transaction by Vor Biopharma Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Vor Biopharma Fundamental Analysis
We analyze Vor Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vor Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vor Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
Vor Biopharma is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Vor Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vor Biopharma stock to make a market-neutral strategy. Peer analysis of Vor Biopharma could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics with similar companies.
Peers
Vor Biopharma Related Equities
| STTK | Shattuck Labs | 10.92 | ||||
| VTYX | Ventyx Biosciences | 8.97 | ||||
| ERAS | Erasca | 6.20 | ||||
| ACLX | Arcellx | 5.59 | ||||
| LYRA | Lyra Therapeutics | 5.00 | ||||
| FHTX | Foghorn Therapeutics | 4.75 | ||||
| ACET | Adicet Bio | 4.65 | ||||
| DSGN | Design Therapeutics | 3.85 | ||||
| KYMR | Kymera Therapeutics | 3.64 | ||||
| KNSA | Kiniksa Pharmaceuticals | 3.31 | ||||
| NRIX | Nurix Therapeutics | 3.00 | ||||
| GLUE | Monte Rosa | 0.92 | ||||
| NUVL | Nuvalent | 0.09 | ||||
| EWTX | Edgewise Therapeutics | 0.83 | ||||
| AUTL | Autolus Therapeutics | 1.14 | ||||
| CGEM | Cullinan Oncology | 1.39 | ||||
| BOLT | Bolt Biotherapeutics | 2.08 | ||||
| DAWN | Day One | 4.03 |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.